Introduction
============

I will describe here the way in which I was able to discover that yeast has prions (infectious proteins), proteins that are the carriers of genetic information, and thus are acting as genes ([@B1]). This startling finding involved inventing new genetic approaches, but was possible because of my particular background and interests. Our work has broadened the "prion" concept (originally thought to be restricted to a special mammalian disease), established that there are such things as genes made of protein, and led to an understanding of how proteins can encode and transmit heritable information.

My undergraduate degree was from Cornell University in mathematics. This early interest proved important in guiding me into genetics, which I have always viewed as the "logic of life" and, more recently, as I have become involved in solid-state NMR studies. I received an M.D. degree from Georgetown University, and, following a medical internship, I became a postdoctoral fellow with Herb Tabor at the National Institutes of Health (NIH). This was my first real experience doing science, and Herb\'s critical, careful attitude toward research was my guide in establishing my own approach. I found that adenosylmethionine decarboxylase, the product of which is an intermediate in spermidine biosynthesis, has a pyruvoyl residue as a prosthetic group ([@B2]) and that histidine ammonia-lyase has a similar prosthetic group, dehydroalanine ([@B3]). As a postdoctoral fellow with Jerry Hurwitz at Albert Einstein College of Medicine in New York, I learned about nucleic acid enzymology from "The Boss" and worked on *Escherichia coli* DNA polymerase II and *in vitro* DNA replication ([@B4], [@B5]). I was impressed that the *dna^ts^* mutants, isolated by Jacob, Bonhoeffer, Carl, Wechsler, and others, were the key to the biochemistry of DNA replication, coupled with *in vitro* replication systems selected to require the *dna* gene products ([@B6]). *In vitro* complementation could be used to purify the proteins shown by *in vivo* studies to be responsible for the biochemical reaction. These experiences having provided me with a firm biochemical background, I then took the 3-week Cold Spring Harbor Laboratory course on yeast genetics, taught by Fred Sherman and Gerry Fink.

I began my independent work in the laboratory of Jerry Hurwitz, who generously allowed me to start working on yeast genetics for a year until my job at the NIH began in 1973. I started out purifying DNA polymerases from yeast, similar to what I had been doing as a postdoctoral fellow with Jerry, but I decided that yeast genetics might be a better route to answering even many biochemical issues. I isolated mutants that could take up dTMP for labeling cellular DNA. These mutants were not widely used for this purpose, but proved quite interesting, particularly *tup1* mutants, which had a mating-type α-specific mating defect and a sporulation defect ([@B7]) and proved to be a subunit of a transcriptional repressor ([@B8], [@B9]).

The key role that bacteriophage had played in the development of an understanding of bacterial genetics led me to focus on the non-chromosomal genetic element determining the killer trait of yeast ([@B10]--[@B12]), then newly discovered to involve a double-stranded RNA (dsRNA) in virus particles ([@B13]--[@B15]). We isolated mutants in host genes necessary for propagation of the killer toxin-encoding M dsRNA (a satellite of the L-A dsRNA virus), mutants that could propagate M dsRNA but could not express the killer phenotype (*kex* mutants), and [s]{.ul}uper[ki]{.ul}llers (*ski*). In an era before yeast cloning, we genetically mapped them as a means of identification.

Major Findings on Yeast Viruses
===============================

Our findings on yeast viruses are summarized here. 1) With Steve Sommer, Micheline Wesolowski, and Yutaka Matsumoto, we found there are at least four independent RNA replicons in many strains, namely the L-A virus (4.6 kb, dsRNA), the L-BC virus (also 4.6 kb, dsRNA), and the T and W dsRNAs, forms of the 20 S and 23 S single-stranded RNA replicons ([@B16]--[@B19]). The latter two replicons have been studied in depth by Rosa Esteban and Tsutomu Fujimura in Salamanca, Spain. 2) Natural variants of the L-A virus interfere with each other and vary in their ability to propagate the M dsRNA satellite RNAs ([@B20], [@B21]). 3) Rosa Esteban and I demonstrated "head-full replication" of the dsRNAs, with intraviral replication until the viral head is full and then extrusion of new (+)-strands for translation and formation of new particles ([@B22]). 4) Juan Carlos Tercero and I found a new protein *N*-acetyltransferase (Mak3p) whose N-terminal acetylation of the major L-A coat protein is necessary for virus assembly ([@B23]). 5) Yasuyuki Ohtake and I showed that the level of 60 S ribosomal subunits is critical for L-A virus and particularly M satellite propagation ([@B24]), and Herman Edskes showed that this is probably because the viral mRNAs lack poly(A) ([@B25]). 6) Akio Toh-e, Steve Sommer, Porter Ridley, and Lionel Benard found seven genes that we named *SKI* genes (for superkiller) and that Dan Masison and Bill Widner showed limit the expression of virus information by limiting the expression of non-poly(A) mRNAs (such as the viral mRNAs) ([@B26], [@B27]). These genes have homologs in all eukaryotes, and we showed they are critical for preventing viral pathology ([@B27]--[@B31]). In fact, Anji Searfoss showed that yeast cells deleted for *ski2* and its homolog, *slh1*, translate poly(A)^−^ and poly(A)^+^ mRNAs with equal efficiency and the same kinetics ([@B32]). The translation apparatus does not really need the 3′-poly(A) on the mRNA. 7) Tsutomu Fujimura established *in vitro* packaging, replication, and transcription systems for L-A, the first for a dsRNA virus, and, with Rosa Esteban and later with Juan Carlos Ribas, we used these systems and genetic experiments to define the RNA sites determining genome packaging and replication and the protein domains required for these processes ([@B33]). Much of this work provided a model for later work on mammalian dsRNA viruses ([@B34]). 8) Tateo Icho and Tsutomu Fujimura showed that the L-A virus expresses a gag-pol fusion protein ([@B35], [@B36]), and Jon Dinman showed that this occurs by ribosomal frameshifting, much like retroviruses ([@B37]). Jon\'s detailed characterization of this process defined the RNA signals controlling frameshifting and the influence of various genes ([@B38], [@B39]), and he has gone on to extensively explore this area ([@B40], [@B41]). 9) Simple size and density measurements by Rosa Esteban showed that the L-A virus has ∼120 subunits per particle. This was supposed to be a forbidden symmetry, but we suggested that the virus had *T* = 1 symmetry with an asymmetric dimer as the unit element ([@B22]). Cryo-EM studies ([@B42]) and the x-ray diffraction structure of the particles obtained by Jack Johnson\'s group ([@B43]) showed that our speculation was correct. It proved to be true of the cores of mammalian dsRNA viruses as well. 10) Our *kex1* and *kex2* ([k]{.ul}iller [ex]{.ul}pression) mutants, which were unable to produce active killer toxin or α-pheromone ([@B44]), led to the discovery by others of homologous enzymes responsible for processing insulin and other prohormones in mammals ([@B45], [@B46]).

Pathway to Discovery of Yeast Prions
====================================

Two aspects of the virus system put us in a position to discover yeast prions. The structure and biochemistry of the L-A virus and the M satellite dsRNA were the same as those of the cores of mammalian dsRNA viruses, and yet the yeast viruses were not able to leave one infected cell and enter another except by artificial means. The yeast viruses spread horizontally when infected cells mate with uninfected cells, and the meiotic progeny all have the viruses. In fact, there are animal and plant viruses that propagate in this way. We thus expected that a yeast infectious protein would have the same property of appearing as a non-chromosomal genetic element. The second point, which was really central, was that our extensive studies of the *mak* mutants, which were unable to propagate the killer toxin-encoding M dsRNA, prepared us to expect that such mutants would (of course) have a phenotype due to the loss of the M dsRNA (lack of toxin production), a phenotype *opposite* to that of the presence of the M dsRNA. Thus, when we saw in the literature a non-chromosomal genetic element with a phenotype the *same* as that of a recessive mutant in a chromosomal gene necessary for the propagation of the non-chromosomal element, we knew that there must be an interesting explanation.

Original Description of \[PSI^+^\] and \[URE3\] by Cox and Lacroute
===================================================================

In 1965, Brian Cox described a non-chromosomal genetic element (\[PSI^+^\]) that enhanced a weak nonsense suppressor, *SUQ5* ([@B47]). He used the *ade2-1* mutation, a premature UAA terminator, which resulted in the accumulation of a red pigment derived from the Ade2p substrate, phosphoribosylaminoimidazole. *SUQ5* proved to be a serine-inserting tRNA mutant that reads the UAA codon, albeit poorly ([@B48]). When the \[PSI^+^\] genetic element was also present, the read-through of the premature UAA stop codon in the *ade2-1* gene was efficient enough to allow cell growth without adenine.

In 1971, while studying uracil biosynthesis, Francois Lacroute found that cells with a block in the first step, aspartate transcarbamylase (*ura2*), could not grow on the product of that enzyme, ureidosuccinate. When he isolated cells that could use ureidosuccinate, he found chromosomal mutants, which he named *ure1* and *ure2*, and a non-chromosomal mutant, which he designated \[URE3\] ([@B49]). With Lacroute, Michel Aigle made the key finding that mutants in *ure2* could not propagate the \[URE3\] genetic element ([@B50])! Thus, recessive *ure2* mutants with the *same* mutant phenotype as the presence of the \[URE3\] element could not propagate \[URE3\]. I saw that this relationship was different from that of the many *mak* mutants I had isolated and studied with the killer toxin-encoding M dsRNA. But what did that relationship mean?

Properties of \[URE3\] Suggested That It Is a Prion of Ure2p
============================================================

In 1989, when I began these studies, I was aware that the infectious agent of the mammalian transmissible spongiform encephalopathies (TSEs) had been suggested to be an infectious protein ([@B51]--[@B53]), although the evidence for that conclusion was far from complete, and there was a great deal of disagreement in the field. Indeed, some of the data thought to be strongly supportive of the "protein-only" model proved later to have other explanations. On discovering prion protein (PrP) as the main protein constituent of the purified infectious agent, Prusiner coined the term prion to represent such an entity ([@B53]).

It was clear to me that a yeast prion would have properties quite different from those of the mammalian TSEs. In the mammalian disease, accumulation of a toxic form of the PrP protein in the non-growing central nervous system was believed to produce the fatal TSEs. Because yeast is often growing (at least under laboratory conditions), it seemed to me then that accumulation of something toxic would not likely be a problem (but see below). In thinking what properties one would expect of a yeast prion, the prion\'s being lethal or benign seemed to me to be irrelevant, just as viruses can be benign or lethal. Rather, I sought genetic features that would not depend on the particular phenotype produced by the prion.

The fact that the *URE2* gene is necessary for the \[URE3\] non-chromosomal genetic element and yet *ure2* mutants have the *same* phenotype as the presence of \[URE3\] ([@B50]) struck me as just what one would expect of a prion of Ure2p. Either the *ure2* mutation or the conversion to the prion form (whatever that may be) should inactivate Ure2p and produce the same or a similar phenotype in each case. This became the first of my "genetic criteria for a yeast prion" ([Fig. 1](#F1){ref-type="fig"}) ([@B1]). Note that this is not a property of the mammalian prion. Deletion of the gene encoding PrP produces no clear phenotype, although the presence of the prion (a TSE) is uniformly lethal. Interestingly, although not mentioned in the published paper that I read ([@B50]), Michel Aigle, in his master\'s thesis, inferred part of the prion explanation of \[URE3\] to explain his result: "Le facteur \[URE3\] rendrait donc non fonctionnel le produit du gene (URE 2-+)." (The \[URE3\] factor thus rendered nonfunctional the product of the *URE2* gene.)

![**Three genetic criteria for a prion of yeast ([@B1]).** I proposed that these properties are expected of prions but not of nucleic acid replicons (viruses or plasmids) and so should allow diagnosis of yeast prions among non-chromosomal genetic elements.](zbc0191206160001){#F1}

I tried to think what other genetic properties would distinguish a prion of yeast from a nucleic acid replicon. Bacterial plasmids are often curable by intercalating agents, and yeast mitochondrial DNA is efficiently cured by growth on ethidium bromide. The dsRNA viruses are cured by growth of cells at elevated temperatures. Thus, a given curing agent may or may not cure a nucleic acid replicon, but, for each of the above cases, the cured cells stay cured unless the virus or plasmid is introduced from elsewhere, by mating, transformation, or, in some bacteria, conjugation. In contrast, a prion could arise again spontaneously in the cured strain at some low frequency because the protein capable of conversion to the self-propagating altered form is always present in the cells ([@B1]). I called this "reversible curability" ([Fig. 1](#F1){ref-type="fig"}). The \[PSI^+^\] prion had been shown to be cured by growth in high osmotic media ([@B54]), but cells cured in this way could again become \[PSI^+^\] ([@B55]). I tested whether \[URE3\] could be cured by guanidine, as previously reported for \[PSI^+^\] ([@B56]), and it was indeed cured ([@B1]). From the cured strains, I could isolate \[URE3\] derivatives at frequencies similar to those at which they arose originally ([@B1]), so \[URE3\] satisfied this genetic criteria for a prion.

Because a prion must be based on a self-propagating change, the generation of the prion form in a cell should take over the population of molecules of the prion protein. I surmised that the larger the population of prion proteins, the more frequently the prion change should occur ([Fig. 1](#F1){ref-type="fig"}) ([@B1]). The gene for the prion protein should, of course, be a gene needed for the propagation of the prion. Plasmids and viruses of yeast also will depend on chromosomally encoded proteins for their propagation, but, in contrast to the prion case, overproduction of one of those proteins would not induce the *de novo* generation of the virus or plasmid. This approach provides (*a*) evidence that a particular non-chromosomal genetic element is a prion, (*b*) a concrete means for generating the prion formation, and (*c*) a way to find which protein encodes a given putative prion protein. Indeed, when I tested whether the frequency of \[URE3\] arising was enhanced by overproduction of Ure2p, I found a robust 100--200-fold effect ([@B1]). I can still remember my excitement when this experiment turned out just the way I had expected.

None of my three genetic criteria for a yeast prion ([Fig. 1](#F1){ref-type="fig"}) are known to be true of mammalian prions. There is no way to cure the TSEs, and, even if there were, there would be no way of demonstrating spontaneous generation of mammalian prions in a wild-type mouse because it would be too rare. Overexpression of PrP is known to kill mice ([@B57]), but their tissues are not infectious, so prions have not been generated. Deletion of the *Prnp* gene encoding PrP has no phenotype, unlike the lethal phenotype of a TSE.

Reinterpretation of the Old \[PSI^+^\] and \[URE3\] Literature
==============================================================

The fact that \[URE3\] satisfied all three genetic criteria for a prion of Ure2p led me to examine whether other orphan non-chromosomal genetic elements could also be prions ([@B1]). \[PSI^+^\] had been extensively studied, mostly by its discoverer, Brian Cox, and his colleagues, particularly Mick Tuite, and also by Fred Sherman and Sue Liebman. Michael Ter-Avanesyan\'s group in Moscow and Yury Chernoff, then a student of Sergey Inge-Vechtomov and later a postdoctoral fellow with Bun-Ichiro Ono and Sue Liebman, did key experiments.

As mentioned above, Singh and Sherman had found that high osmotic strength cured \[PSI^+^\], but Lund and Cox found that \[PSI^+^\] clones could be isolated from a cured strain. On overproduction of Sup35p, the frequency of \[PSI^+^\] arising was dramatically increased ([@B58]). Finally, \[PSI^+^\] propagation depends on the *SUP35* gene ([@B59]), but the phenotype of \[PSI^+^\] and that of *sup35* mutants are similar. The original *sup35* mutants were recessive "omnipotent suppressors," meaning that they would suppress UAA, UAG, or UGA nonsense codons ([@B60], [@B61]). We reinterpreted these results as evidence that \[PSI^+^\] was a prion of Sup35p ([@B1]). Subsequently, our "genetic criteria" have been central to the identification of other yeast and fungal prions ([@B62]--[@B66]). For example, \[Het-s\] is a prion of the HET-s protein from *Podospora anserina* involved in heterokaryon incompatibility ([@B62]), and \[PIN^+^\] is a prion of yeast Rnq1p ([@B63]). The dominance of \[URE3\] over its absence (denoted \[ure-o\]) or the dominance of \[PSI^+^\] over \[psi^−^\] would not mean that the prion form is active in regulating nitrogen catabolism or translation termination, rather that the prion form inactivates the active form by converting it into the prion form.

We found that the overproduction of just the first 65 residues of Ure2p was sufficient to induce *de novo* generation of \[URE3\] and was actually ∼100 times more efficient than the full-length protein in doing so ([Fig. 2](#F2){ref-type="fig"}) ([@B67]). The same fragment was also sufficient to propagate \[URE3\] in the complete absence of the remainder of the protein ([@B68]). We named this the "prion domain." Earlier elegant studies by Michael Ter-Avanesyan and colleagues showed that the N-terminal 114 amino acid residues of Sup35p are dispensable for growth but necessary for propagation of the \[PSI^+^\] prion ([@B69]); we reinterpreted this as the Sup35p prion domain ([Fig. 2](#F2){ref-type="fig"}) ([@B67]).

![**Domain structure of yeast and fungal prion proteins.** The N-terminal domains of Ure2p and Sup35p have cellular functions, constitute the portion of the molecule necessary and sufficient for prion propagation, and comprise the core of the amyloid.](zbc0191206160002){#F2}

\[PSI^+^\] and \[URE3\] Prions Are Based on Amyloid Forms of Sup35p and Ure2p
=============================================================================

Although the genetic criteria provided strong evidence that \[PSI^+^\] and \[URE3\] are prions of Sup35p and Ure2p, respectively, they did not provide clues to the mechanism of prion action, how a protein could transmit an infection. Dan Masison, in my group, obtained the first biochemical evidence for yeast prions in showing that a fragment of Ure2p is protease-resistant specifically in \[URE3\] prion-containing cells ([@B67]), reminiscent of the remarkable protease resistance of PrP in brains of animals infected with a TSE ([@B53]), a reflection of the amyloid form of PrP in the disease. Amyloid is a filamentous polymer of protein monomers composed of β-strands perpendicular to the long axis of the filaments ([@B70]). Amyloids of various proteins are also key to the pathogenesis of Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis, and amyloid is important in adult-onset diabetes mellitus. Yury Chernoff, in Sue Liebman\'s laboratory, found that Hsp104p, a disaggregating chaperone, was critical for the propagation of the \[PSI^+^\] prion, suggesting that protein refolding might be important in prion formation ([@B71]).

Paushkin *et al.* ([@B72]) showed that the self-propagating inactivation of Sup35p *in vivo* was paralleled by the self-propagating aggregation of Sup35p *in vitro* and were first to suggest that the role of Hsp104p in prion propagation was the breakup of aggregates to make new seeds. King and Wüthrich ([@B73]) were first to show that a yeast prion domain (of Sup35p) could form amyloid *in vitro*, and Glover *et al.* ([@B74]) showed that extracts of \[PSI^+^\] cells could seed amyloid formation by Sup35NM, including the prion domain. Herman Edskes showed that Ure2p is aggregated in \[URE3\] cells ([@B75]). Moreover, Kim Taylor found that Ure2p forms amyloid *in vitro*, and, just as the Ure2p prion domain is necessary for *in vivo* prion formation, it is required for *in vitro* amyloid formation ([@B76]). The Ure2p prion domain that can initiate prion formation *in vivo* can likewise speed amyloid formation by the full-length protein *in vitro* ([@B76]).

The ease of yeast genetics made possible convincing evidence of yeast prions as described above, but, in mammals, some of these approaches were impossible. As a result, attempts to infect animals with amyloid made of recombinant PrP protein has been a critical goal. This was first achieved for the fungal prion \[Het-s\] (described in more detail below) by Marie-Lise Maddelein in Sven Saupe\'s group, who showed that amyloid of recombinant HET-s protein efficiently infected fungal cells with the \[Het-s\] prion, but that the soluble form, or non-amyloid aggregates, did not ([@B77]). It was then shown that \[PSI^+^\] ([@B78], [@B79]) and, later, \[URE3\] and \[PIN^+^\] ([@B80], [@B81]) could also be infected with amyloids of the prion domains of Sup35p, Ure2p, and Rnq1p.

\[β\], a Prion Unrelated to Amyloid Formation
=============================================

The definition of prion is "infectious protein" and does not require a role for amyloid formation ([@B53]). We showed that the self-processing vacuolar protease B of yeast (Prb1p) could be the basis for a prion. Prb1p is made as an inactive precursor that is normally processed by protease A (Pep4p) to form the mature active form ([@B82]). Zubenko *et al.* ([@B83]) showed that active Prb1p could also activate the Prb1 precursor in the absence of protease A. Tibor Roberts and I showed that this self-activation could continue indefinitely under conditions that derepress Prb1p synthesis and that this phenomenon has all the properties of a prion ([@B64]). In this case, the active protease B is the prion form.

Protein Sequence *Versus* Amino Acid Content in Determination of Prion-forming Ability
======================================================================================

A close similarity of prion protein sequence in donor and recipient has long been known as a critical condition for transmission of prion infection; in some cases, even a single amino acid difference can prevent transmission ([@B59], [@B84]). This is the extreme case of the "species barrier," the delayed or blocked transmission of infection from one species to another (*e.g.* Ref. [@B85]). In some cases, the altered sequence can form a prion on its own, even though it cannot be infected by the prion from the wild-type sequence (*e.g.* Ref. [@B86]).

With the intention of proving that the sequence of the Ure2p prion domain was important for prion formation, Eric Ross, in my laboratory, replaced the normal prion domain with each of five randomly shuffled versions of this region in which the amino acid content was preserved but the sequence was randomized ([@B87]). Surprisingly, each of these shuffled domains could support *de novo* prion formation, and he obtained the same result for the prion domain of Sup35p ([@B88]). These results showed that, at least for these prion domains, it is the amino acid content, not the sequence, that determines the ability to form a prion. Ross has pursued this area independently and determined what compositional components are critical for prion formation and used this information to create a "designer prion" ([@B89], [@B90]).

Yeast Prions Are In-register Parallel Amyloids: Structure Explaining Biology
============================================================================

From the prion domain shuffling results, we inferred that the amyloid underlying these yeast prions must have an in-register parallel architecture ([@B91]). The requirement for sequence near-identity for prion propagation implies a favorable interaction between amino acid side chains. If this interaction were between different, perhaps complementary side chains (like the complementarity of DNA strands), shuffling the prion domain sequence would destroy the complementarity (as it does the hybridization of complementary DNA chains), but if the interaction were between identical side chains (in an in-register parallel structure), shuffling the sequence would leave the side chains still able to have the favorable interactions, just in a different sequence.

To test this reasoning, Frank Shewmaker, Ulrich Baxa, and I collaborated with Rob Tycko, an outstanding solid-state NMR expert who had already shown that amyloid fibers of amyloid β, the central pathogenic element of Alzheimer disease, is an in-register parallel β-sheet structure ([@B92]). The high infectivity of amyloid formed *in vitro* from recombinant yeast and fungal prion proteins, not yet possible with mammalian prion protein, meant that we were studying the structure of the right stuff. A dipolar recoupling experiment, which measures the distance from one ^13^C-labeled atom to the next nearest labeled atom, can be used to distinguish the in-register parallel architecture from antiparallel, β-helix, or parallel out-of-register structures. Molecules are labeled at one or a few carbonyl carbons, and, in the in-register parallel case, this distance will be ∼4.8 Å, the distance between adjacent β-strands ([@B93]). For the other architectures, the distance will generally be twice 4.8 Å or greater. Using highly infectious amyloid of the prion domains of Sup35p, Ure2p, and Rnq1p labeled with the α-carbonyl carbon in any of several different amino acid residues, we consistently found a distance of ∼5 Å in such experiments ([@B94]--[@B96]). Making amyloid fibers from a mixture of labeled and unlabeled molecules showed that the nearest neighbor was on a different molecule, as expected for the in-register parallel structure. Frank Shewmaker and I showed that filaments of Sup35p conferring different prion variants on infection into yeast each had this architecture ([@B97]), and the shuffled prion domains had the same architecture, as predicted ([@B98]). This adventure into NMR was especially satisfying to me because it gave me an excuse to pursue my long-standing interest in math and physics on company time. Rob Tycko was particularly generous of his time and instruction, not only doing many of the experiments but also teaching me some of the basics and letting me use his NMR spectrometers.

Measurements of mass per unit length of Ure2p and Sup35p amyloid fibers show a single molecule per ∼4.7 Å, consistent with the in-register parallel architecture ([Fig. 3](#F3){ref-type="fig"}) ([@B99]--[@B101]) but, significantly, ruling out a β-helix (such as is found in the HET-s amyloid ([@B102])) or several other possibilities. The in-register parallel architecture determines much of the structure, but, if the entire prion domain of even the ∼65-residue Ure2p prion domain were in a single flat sheet, filaments would be \>20 nm wide. In fact, they are only ∼4--5 nm wide, indicating that the sheet must be folded several times lengthwise, as diagrammed in [Fig. 3](#F3){ref-type="fig"}. We hypothesized that different prion variants have these folds in different locations ([@B103]--[@B105]).

![The in-register parallel β-sheet architecture with longitudinal folds of yeast prion amyloid filaments can explain transmission of conformational information to monomers joining the end of the filament. The same interactions among aligned identical amino acid side chains that hold the structure in-register also drive the monomer joining the end of the filament to have the same conformation as the molecules already in the filament ([@B103], [@B106]).](zbc0191206160003){#F3}

How Does a Protein Template Its Own Conformation?
=================================================

The fact that any of a variety of TSE variants ("strains") can propagate in mice with the same PrP protein sequence made many skeptical of the prion hypothesis because no mechanism for propagation of conformation was even hypothesized. We have proposed that the same positive interactions between identical amino acid side chains that maintain the structure in-register also drive the monomer joining the end of the filament into the same conformation as the monomer already on the end of the filament and, thus, as all the other molecules in the filament. These positive interactions, hydrogen bonds between the side chains of aligned glutamine, asparagine, serine, or threonines residues or hydrophobic interactions among aligned leucine, valine, isoleucine, tyrosine, or phenylalanine residues, are possible if the sequences are aligned, but not if they are off by even a single residue. The turns of each strand will be forced to occur at the same point on the peptide chain in each new molecule joining the end of the filament ([Fig. 3](#F3){ref-type="fig"}). In this way, a protein can template its own conformation, just as a DNA strand can template its own sequence ([@B103]--[@B106]).

Biology of Yeast Prions: a Help or a Hindrance?
===============================================

The description by Sven Saupe and coworkers in Bordeaux, France, of a prion, \[Het-s\], from the filamentous fungus *P. anserina* involved in a normal fungal function, heterokaryon incompatibility ([@B62]), led me to suggest that this was the first case of a potentially beneficial prion ([@B107]). However, later work showed that \[Het-s\] is also involved in a meiotic drive phenomenon, detrimental to the host but promoting the spread of the *het-s* allele encoding the prion protein ([@B108]). Perhaps both are driving the evolution of *het-s*, but it seems certain that the HET-s protein has evolved to be a specific prion.

The commonly used strains with \[PSI^+^\] or \[URE3\] appear to grow well in the laboratory, but perhaps they are commonly used for this reason, and no consistent reproducible benefit of being \[PSI^+^\] or \[URE3\] has been reported. To address the benefit *versus* detriment issue, we reflected that even lethal prions are often found in nature (scrapie and chronic wasting disease) because their infectivity outruns the damage they do to their hosts. A beneficial prion, for which infectivity and effect on the host would be working together to promote its spread, instead of in opposition, would quickly become nearly universal in the wild. Thus, a prion that is not found in the wild must be a substantial detriment to its host. Toru Nakayashiki and I surveyed 70 wild-type strains and found each of the known parasitic non-chromosomal nucleic acid replicons (viruses and plasmids) in various proportions of the strains, but none carried the \[PSI^+^\] or \[URE3\] prion ([@B109]). This is a sort of sum over all conditions and tells us that the net result of these prions is detrimental.

Dan Masison\'s group showed that infection of yeast by the \[URE3\] and \[PSI^+^\] prions induces the increased expression of stress proteins Hsp104 and Hsp70s, indicating that the cell views them as detrimental (a stress) ([@B110], [@B111]). Our naming the regions responsible for prion formation "prion domains" may have been an unfortunate choice, as it apparently made others think that this is the function of these domains. In fact, the prion domain of Sup35p has a normal non-prion role in promoting normal turnover of mRNAs by interacting with the poly(A)-binding protein and with the poly(A)-degrading nucleases ([@B112]--[@B114]). Frank Shewmaker showed that the Ure2p prion domain is required for the normal stability of the protein against degradation, so deletion of this part results in a partially defective phenotype ([@B115]). Calling these parts of Ure2p and Sup35p the "prion domains" might be like calling the humerus the "broken arm domain."

The sequence conservation of the Ure2p and Sup35p prion domains is probably to conserve the non-prion functions of these domains (see above) and is thus not an argument that prions must benefit the host. Indeed, as discussed above, sequence need not be conserved to preserve prion-forming ability in these cases. Moreover, prion-forming ability is not in fact generally conserved. For example, the N-terminal domain of the *Candida glabrata* Ure2p is similar in sequence to the *Saccharomyces cerevisiae* Ure2p prion domain, but it cannot form a prion ([@B116], [@B117]). In contrast, the N-terminal domain of the *Candida albicans* Ure2p is much less similar to that of *S. cerevisiae*, but readily forms a prion ([@B116]). In addition, Ure2p of *Kluyveromyces lactis* and that of *Saccharomyces castellii* are each unable to form prions ([@B118], [@B119]).

Scrapie, the prion disease of sheep, has been common in the West for centuries ([@B120]) and perhaps for millennia in the East ([@B121]). Probably as a result, there have arisen alleles of sheep PrP that are resistant to scrapie infection ([@B122]). The incidence of human TSE is limited by a polymorphism at residue 129, which can be Met or Val. Homozygotes of either Met/Met or Val/Val can have Creutzfeldt-Jakob disease, but heterozygotes rarely develop the disease ([@B123]). David Bateman found that polymorphisms in the N and M domains of Sup35p likewise limit the spread of \[PSI^+^\] in *S. cerevisiae* ([@B124]). We suggest that these polymorphisms became widespread because \[PSI^+^\] is not good for yeast.

Although the commonly studied variants of \[URE3\] and \[PSI^+^\] grow well, we suspected that there could easily be \[PSI^+^\] variants that soak up all of the Sup35p into amyloid filaments and thus be lethal. Ryan McGlinchey detected such "suicidal" \[PSI^+^\] variants, as well as very sick variants constituting over half of all \[PSI^+^\] isolates ([@B125]). Dmitry Kryndushkin found frequent \[URE3\] isolates that produce extremely slow cell growth in a background in which deletion of *URE2* does not slow growth at all, indicating that this prion as well can be devastating, but by a toxic mechanism, not simply depletion of Ure2p ([@B125]). Certain mutants in *SIS1*, encoding an Hsp40 protein, make even the usual mild \[PSI^+^\] variants become lethal to the cell, again emphasizing the danger of being \[PSI^+^\] ([@B126]). These results show that the impact of acquiring either of these prions is not as benign as previously thought.

Thus, a variety of lines of evidence indicate that the yeast prions \[URE3\] and \[PSI^+^\] are detriment to their hosts. It remains possible that some variant of one of these prions or another prion will be found to be beneficial under some condition. However, it is already clear that these two prions are detrimental on the whole.

Prospects for Future Work on Yeast Prions
=========================================

It is very satisfying to me that my work on the relatively obscure yeast killer virus led to our discovery of protein-based inheritance, a concept of broad interest. As models for the mammalian TSEs, yeast prions have dramatically advanced our understanding of what a prion can be and how information may be encoded in a protein and even provided the most convincing evidence that there can be such a thing as a prion. Recently, work on other mammalian amyloidoses has advanced the notion that many involve similar mechanisms of spread within the body, that several are transmissible by injection, and that a few may even be naturally infectious (reviewed in Refs. [@B127] and [@B128]). Unlike the rare TSEs, these amyloid diseases are widespread, and it is clear that the yeast prion systems can provide important information with a wide application in their study. We expect that studies of the mechanisms by which yeast prions are generated, propagate, and produce pathology in their hosts will continue to produce insights important for the wider field of amyloid diseases.

I am grateful to all of the bright and dedicated people who have worked with me over the years. I also want to express special thanks to Herb Tabor, who got me started in research, and to my long time collaborator, Herman Edskes.
